Company Profile

Melior Discovery Inc
Profile last edited on: 6/2/17      CAGE: 5D6P7      UEI: XS2QB3V9VQT4

Business Identifier: Proprietary drug discovery platform; novel therapeutic candidates across broad range of therapeutic targets
Year Founded
2005
First Award
2014
Latest Award
2014
Program Status
Inactive
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

860 Springdale Drive
Exton, PA 19341
   (610) 280-0633
   bizdev@meliordiscovery.com
   www.meliordiscovery.com
Location: Single
Congr. District: 06
County: Chester

Public Profile

Melior Discovery Inc has pioneered a unique “high throughput” in vivo pharmacology platform (theraTRACE®) able systematically to identify novel indications for pre-clinical and development stage drugs. theraTRACE® is widely used by both multinational pharmaceutical and start-up biopharmaceutical companies alike to fully explore the therapeutic potential of their drug candidates. Melior has leveraged this expertise to build a high quality, onshore, preclinical services capability offering in vivo efficacy models in a broad range of therapeutic areas, pharmacokinetic evaluations, specialized animal models and bioanalytical services to drug developers world

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
25-49
Revenue Range
2.5M-5M
VC funded?
Yes
Public/Private
Privately Held
Stock Info
----
IP Holdings
1-4

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2014 1 NIH $224,981
Project Title: Pharmacological Evaluation of MLR-1023: Studies to Confirm Efficacy; Establish A

Key People / Management

  Andrew G Reaume -- President And Chief Executive Officer

  Michael S Saporito -- Vice President, Research and Development